EBD Group and MassBio bring BioPharm America™ back to Boston
Leading partnering event returns September 7–9, 2011
Carlsbad, CA and Cambridge, MA – EBD Group and MassBio today announced a continued collaboration that will bring one of the largest and most productive partnering events in North America back to Boston this fall. BioPharm America™—which drew more than 900 people to Boston in 2010—will be held September 7–9, 2011 at the Westin Waterfront.
BioPharm America continues its growth as the unrivaled business exchange in North America for the global life science industry, specifically designed to help companies raise capital, form in- or out-licensing agreements, and enter co-development deals.
In addition to pulling together the large and active participation of the international and Massachusetts-based life science community, BioPharm America 2011 features partneringONE®, the industry’s most advanced partnering system. The event also features a topnotch program that includes the Defined Health Therapeutic Insight track, a finance/investment track, a personalized medicine track and dozens of company presentations. Working together, these powerful elements create a unique platform where companies can efficiently identify and meet with potential partners from across the life science value chain, and gain the intelligence needed to make better deals.
Carola Schropp, President of EBD Group, said, “Partnering is essential to continued innovation in the life science industry. That is why we are bringing our leading partnering platform back to Boston, which is the premier hub of life science innovation. Partnering at BioPharm America will enable emerging biotech innovators and large pharmaceutical firms to accelerate their strategic plans.”
Robert K. Coughlin, President and CEO at MassBio, said, “We are proud to host this unique, high powered business exchange that so effectively brings together the international biotech partnering and financial communities here in Boston in 2011. With Massachusetts’ strength in innovation and early stage research, active venture capital and finance community, and participation from all the major pharma companies, the stage is set for BioPharm America 2011 to be the premier conference on the East Coast.”
MassBio estimates that 1,273 biotechnology drugs were being developed in Massachusetts in 2009, representing almost eight percent of the global drug pipeline. In 2010, Massachusetts companies garnered more than 23 percent of all of the biotechnology venture capital funding in the United States, an all-time high.